High Purity 99% Pure Ticagrelor CAS 274693-27-5 Apis Raw Material

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Ticagrelor
• Grade: Pharmaceutical Grade
• Appearance: White Powder
• CAS No: 274693-27-5
• Shelf Life: 2 Years
• Test Method: HPLC
• Application: Health Care Supplements
• Form: Powder
• Storage: Store Cool Dry Place
• Shipping Methods: DHL, FedEx, TNT, EMS, UPS, etc
• Shipping Area: Worldwide/All Countries
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

High Purity 99% Pure Ticagrelor CAS 274693-27-5 Apis Raw Material

 

Specification of Analysis

Tests	Specification	Results
Identification	Musculine reaction	Conform
Description	White powder	Conform
Clarity and Color	Should conform	Conform
Specific rotation	-92°~-109°	-97.5°
Other Impurities	≤0.5%	0.16%
Loss on drying	≤3.0%	2.0%
Limit of(R)-olfx	≤1.0%	0.45%
Residue on ignition	≤0.2%	0.05%
Heavy metals	≤0.002%	Conform
Assay	≥98.5%	99.0%

Introducton 

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.

It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.

Function

Ticagrelor is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010.The drug was approved by the US Food and Drug Administration on July 20, 2011.
Ticagrelor is an antagonist of the P2Y12 receptor.

Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation.

Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world's first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.